CONNECTA THERAPEUTICS SL

Central nervous system diseases represent some of the most intractable challenges in modern medicine. Conditions such as multiple sclerosis, neurodegenerative disorders, and severe psychiatric conditions affect hundreds of millions of people worldwide, yet for many of these pathologies the available therapeutic options remain inadequate or ineffective. This is the unmet need that Connecta Therapeutics, a European biotech specializing in innovative CNS treatments, was built to address. Connecta's approach follows the model of the most advanced biotechs: rigorous clinical development combined with a partnership strategy that brings therapies to patients through collaborations with specialized clinical centers, academic research groups, and potential pharmaceutical co-developers. The guiding principle is accessibility — making treatments that currently exist only in experimental form genuinely available to the patients who need them. The business model is built on professional services and custom-developed solutions, an approach that allows flexibility in the type of partnerships the company can activate. Primary customers include clinical centers and research institutions seeking partners for new therapy development, as well as pharmaceutical companies interested in licensing or co-developing CNS treatments originated externally. The market for neurological therapies is among the largest and fastest-growing segments of the pharmaceutical sector, driven by massive unmet demand that is pushing research toward increasingly novel approaches — from gene and cell therapies to next-generation biologics. Connecta Therapeutics enters this landscape with structured clinical development and strategic partnerships designed to shorten the path from research to treatment, in one of the areas where the need for therapeutic innovation is most urgent.